• AtriCure, Inc. recently reported its fourth quarter and full-year 2025 results, with quarterly revenue of US$140.5 million, a swing to net income of US$1.76 million, and substantially reduced full-year losses alongside 2025 revenue of US$534.53 million.
• Management also issued 2026 guidance calling for US$600 million to US$610 million in revenue and positive net income, while highlighting progress in key clinical programs and new product launches that could influence the company’s market reach and profitability profile.
• With management now targeting positive 2026 net income, we’ll examine how this guidance reshapes AtriCure’s existing investment narrative and expectations.

Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.

AtriCure Investment Narrative Recap

To own AtriCure, you need to believe that its surgical ablation and appendage management franchises, supported by clinical data and new products, can offset competitive and pricing pressures while moving the business into consistent profitability. The latest results and 2026 guidance support that profitability path in the near term, but they do not remove the core risk that pulsed field ablation catheter adoption and international pricing constraints could pressure revenue and margins if these trends intensify.

The most directly relevant recent announcement is AtriCure’s 2026 outlook for US$600 million to US$610 million in revenue and positive net income, coming alongside Q4 2025’s swing to a small profit. This guidance ties near term financial progress to ongoing investments in trials like LeAAPS and BoxX NoAF and product launches, which remain key potential growth drivers but also keep the risk of elevated R&D and SG&A spending front and center.

Yet even with improving profitability, investors should be aware that growing PFA competition could still...

AtriCure's narrative projects $717.8 million revenue and $13.2 million earnings by 2028. This requires 12.8% yearly revenue growth and a $49.6 million earnings increase from -$36.4 million today.

Uncover how AtriCure's forecasts yield a $52.78 fair value, a 60% upside to its current price.

Exploring Other Perspectives

Before this report, the most optimistic analysts were assuming revenue near US$736 million and earnings of about US$19 million by 2028, so if you worry about PFA headwinds but also see the upside in AtriClip adoption, this new guidance might either reinforce or soften that bullish view and is a good prompt to compare how your expectations differ from those more aggressive forecasts.

Explore 2 other fair value estimates on AtriCure - why the stock might be worth less than half the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your AtriCure research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.
• Our free AtriCure research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate AtriCure's overall financial health at a glance.

Curious About Other Options?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Find 56 companies with promising cash flow potential yet trading below their fair value.
• Outshine the giants: these 26 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.